• Citer

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.

par De Caluwe, Alex;Romano, Emanuela;Poortmans, Philip;Gombos, Andrea ;Agostinetto, Elisa;Marta, Guilherme Nader;Denis, Zoe;Drisis, Stylianos;Vandekerkhove, Christophe;Desmet, Antoine;Philippson, Catherine ;Craciun, Ligia;Veys, Isabelle;Larsimont, Denis ;Paesmans, Marianne ;Van Gestel, Dirk ;Salgado, Roberto;Sotiriou, Christos ;Piccart-Gebhart, Martine ;Ignatiadis, Michail ;Buisseret, Laurence
Référence Journal for ImmunoTherapy of Cancer, 11, 12
Publication Publié, 2023-12-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Luminal B breast cancer (BC) presents a worse prognosis when compared with luminal A BC and exhibits a lower sensitivity to chemotherapy and a lower immunogenicity in contrast to non-luminal BC subtypes. The Neo-CheckRay clinical trial investigates the use of stereotactic body radiation therapy (SBRT) directed to the primary tumor in combination with the adenosine pathway inhibitor oleclumab to improve the response to neo-adjuvant immuno-chemotherapy in luminal B BC. The trial consists of a safety run-in followed by a randomized phase II trial. Here, we present the results of the first-in-human safety run-in.